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http://dx.doi.org/10.1016/j.chembiol.2012.08.021Multiple lines of evidence place the
signal transducer and activator of tran-
scription (STAT)3 at a central node in the
development, progression, and mainte-
nance of many human tumors, pointing
to STAT3 as a promising anticancer
target (Aggarwal et al., 2009; Lee et al.,
2011). This transcription factor is constitu-
tively activated by aberrant upstream
tyrosine kinase activity in a broad spec-
trum of human cancers. Of note, the
persistent activation of STAT3 intrinsic to
tumor cells is transmitted to stromal
inflammatory and immune cells in the
tumor microenvironment, establishing
a feed-forward loop that promotes tumor
growth and immunological tolerance.
Activation of STAT3 in dendritic cells
(DC) at the tumor site dramatically
reduces their capacity to promote a T
helper (Th)1 immune response and
favors expansion of both myeloid and
lymphoid suppressor/regulatory cells in
the tumor microenvironment. This mount-
ing evidence suggests that STAT3 and
related pathways may serve as a target
for blocking tumor growth and spreading
and for changing the immunologic micro-
environment surrounding the tumor to
benefit cancer immunotherapy. However,
although several small molecules have
been reported to inhibit STAT3 signaling,
the vast majority act on targets upstream
to STAT3.
In a previously published article in
Chemistry & Biology, Schust et al. (2006)
reported the discovery of a small mole-
cule, named Stattic, which inhibits the
binding of a high affinity phosphopeptide
for the SH2 domain of STAT3. Stattic,
the first developed inhibitor able to bind
STAT3 directly, selectively inhibited acti-
vation, dimerization, and nuclear translo-
cation of STAT3 in response to IL-6.
Conversely, Stattic did not inhibit STAT1
binding and dimerization in response to
IFNg. Blocking STAT3 increased theapoptotic rate of STAT3-dependent
breast cancer cell lines. This important
study challenges the conclusion previ-
ously drawn from the use of other poten-
tial STAT3 inhibitors in terms of direct
binding, potency, and selectivity.
Our group focuses on the development
of strategies for implementing the efficacy
of DC in promoting the induction of
effector anti-tumor immune responses in
immunotherapy protocols. Since STAT3
is a key molecule in the DC-mediated
control of antigen-specific unresponsive-
ness or tolerance, its inhibition may
prove useful to achieve the goal of
enhancing the otherwise insufficient ther-
apeutic response to DC-based vaccines.
We therefore evaluated whether Stattic
could be used to selectively block
STAT3 in human monocyte-derived DC
(MDDC). Similar to what was described
by Schust et al. (2006), Stattic inhibited,
in a concentration dependent manner,
STAT3 phosphorylation at Tyr705 in-
duced by a 15 min treatment with
IL-6 of MDDC (Figure 1A). An even
more potent inhibition of STAT3 phos-
phorylation was observed in response to
IFNb, another cytokine directly activating
STAT3. However, a comparable reduction
of IFNb induced STAT1 and, to a lesser
extent, STAT2 tyrosine phosphorylation,
were also observed in the presence of
Stattic (Figure 1B). We also tested the
effect of Stattic in inhibiting the constitu-
tive STAT3 phosphorylation observed
upon bacterial lipopolysaccharide (LPS)-
induced maturation of MDDC (Gauzzi
et al., 2002). In this experimental setting,
Stattic was used at the concentration of
2 and 10 mM, as the highest dose
(20 mM) proved to be slightly toxic on
prolonged treatments. Similar to what
was observed in response to IFNb, Stattic
was effective in reducing tyrosine phos-
phorylation not only of STAT3, but also
of STAT1 and STAT2 (Figure 1C). Notably,Chemistry & Biology 19, October 26, 2012 ªStattic also inhibited, in a dose dependent
manner, LPS-induced IL-12 production.
Despite some individual variation in the
levels of IL-12 induced by LPS in the
different donors, the presence of 2 mM
Stattic resulted in a reproducible reduc-
tion in IL-12 secretion, which was com-
pletely abrogated in all donors at the
highest dose (Figure 1D).
Taken together, this set of self-
contained data substantially supports
the concept that cell type and/or cytokine
specific effects could modulate Stattic
selectivity toward STAT3. Indeed, such
a caveat was already surmised in the
Preview accompanying the original paper
on the basis of Stattic susceptibility to
Michael addition, which renders themole-
cule a potential target of redox reactions
as well as other biochemical reactions
in different cell types that may affect
pathways other than STAT3 (McMurray,
2006). Furthermore, depending on the
upcoming signal, STAT3 can be recruited
to the triggered receptor and activated
in different homo- or heterodimeric com-
plexes. Both receptor binding and
homo/heterodimerization are mediated
by the SH2 domain; thus, its targeting in
a heterodimeric complex could influence
the activation status of the dimerization
partner(s) too.
Whatever the molecular mechanism
underlying the lack of Stattic specificity
in our experimental setting, we believe
that these data raise a key issue of general
relevance for the design of targeted
anticancer therapies, i.e., the need to
carefully assess the effects of potential
candidates such as Stattic in cells other
than tumor cells and especially in
immune cells. In fact, in cancer patients,
DC exhibit a tolerogenic phenotype,
and breaking their tolerance to tumor
antigens is a main goal for a successful
cancer immunotherapy. Indeed, specific
targeting of STAT3 by RNA interference2012 Elsevier Ltd All rights reserved 1213
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Figure 1. Stattic-Mediated Inhibition of STAT1, STAT2, and STAT3 Activation and IL-12
Secretion in MDDC
(A–C) Monocytes were seeded in RPMI 10% FCS, containing GM-CSF (50 ng/ml) and IL-4 (500 U/ml). At
day 6,MDDCwere pretreated for 1 hr with the indicated concentrations of Stattic and stimulated for 15min
with IL-6 (10 ng/ml) (A) or IFNb (1,000 IU/ml) (B) or 24 hr with LPS (10 ng/ml) (C). STAT expression and
tyrosine phosphorylation in whole-cell extracts was analyzed by western blot. Actin expression is shown
as gel loading control. Data from one representative experiment out of three analyzed are shown.
(D) IL-12 production was assessed by ELISA in the culture supernatant of MDDC treated with LPS in the
presence or absence of Stattic as described in (C). Data are represented asmean ± SEM of three indepen-
dent experiments.
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Correspondenceor genetic inactivation in both mouse and
human DC resulted in an improved
ability to polarize the T cell response
toward a Th1 profile more effective in
inducing antitumor responses and to
resist to cancer cell-derived inhibitory
factors. In keeping with these results,1214 Chemistry & Biology 19, October 26, 20STAT3 depleted DC showed an en-
hanced ability to produce the Th1
promoting-cytokine IL-12 (Iwata-Kajihara
et al., 2011; Kortylewski et al., 2009),
while Stattic treated MDDC were deeply
impaired in IL-12 production in response
to LPS activation. Thus, although power-12 ª2012 Elsevier Ltd All rights reservedful in blocking the aberrant growth of
tumor cells, Stattic could adversely
affect DC activation in the tumor
microenvironment.
In the new era of combining pharmaco-
logical intervention with immunological
approaches to fight cancer, we believe
that our data highlight the importance
of cautiously evaluating promising tools
such as small molecule inhibitors in the
widest range of preclinical models.
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